Spinogenix, Inc. — SEC Form D Filing
Spinogenix, Inc. filed an SEC Form D on March 9, 2026, reporting $10.61M raised in Health Care.
Form D filing details
- Filing
- SEC Form D
- Filing date
- March 9, 2026
- Amount reported
- $10.61M
- Round stage
- Series A
- Industry
- Health Care
- Website
- https://spinogenix.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Spinogenix addresses the challenges posed by neurodegenerative and neuropsychiatric disorders that affect brain synapse functionality.
Solution
The company develops investigational therapeutics that aim to restore brain synapses, thereby improving cognitive and emotional symptoms in affected patients.
Why now
With increasing prevalence of neurodegenerative diseases and a growing need for effective treatments, Spinogenix offers innovative therapeutic solutions at a critical time.
Verdict
Investors backed Spinogenix primarily because of its framing as an innovative solution in an under-addressed area of neurodegenerative diseases, not merely because of the growing market for neurotherapeutics. They were implicitly betting on the unmet medical need coupled with a viable pathway to FDA approval and subsequent commercial adoption, while the limited upside arose from the overcrowded space of neurotherapeutics whereby established players dominate funding and market share.
Source: SEC EDGAR Form D filing